April 2nd 2025
Courtney Flaherty
Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.
April 2nd 2025
Kristi Rosa
Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.
April 2nd 2025
Kristi Rosa
Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.
April 2nd 2025
Jax DiEugenio
Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.
April 2nd 2025
Ashley Chan
A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.